Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022 Featured Updates to the NCCN Guidelines

被引：53

作者：

Wierda, William G. ^{[1
]}

Brown, Jennifer ^{[2
]}

Abramson, Jeremy S. ^{[3
]}

Awan, Farrukh ^{[4
]}

Bilgrami, Syed F. ^{[5
]}

Bociek, Greg ^{[6
]}

Brander, Danielle ^{[7
]}

Chanan-Khan, Asher A. ^{[8
]}

Coutre, Steve E. ^{[9
]}

Davis, Randall S. ^{[10
]}

Eradat, Herbert ^{[11
]}

Fletcher, Christopher D. ^{[12
]}

Gaballa, Sameh ^{[13
]}

Ghobadi, Armin ^{[14
,15
]}

Hamid, Muhammad Saad ^{[16
]}

Hernandez-Ilizaliturri, Francisco ^{[17
]}

Hill, Brian ^{[18
,19
]}

Kaesberg, Paul ^{[20
]}

Kamdar, Manali ^{[21
]}

Kaplan, Lawrence D. ^{[22
]}

Khan, Nadia ^{[23
]}

Kipps, Thomas J. ^{[24
]}

Ma, Shuo ^{[25
]}

Mato, Anthony ^{[26
]}

Mosse, Claudio ^{[27
]}

Schuster, Stephen ^{[28
]}

Siddiqi, Tanya ^{[29
]}

Stephens, Deborah M. ^{[30
]}

Ujjani, Chaitra ^{[31
]}

Wagner-Johnston, Nina ^{[32
]}

Woyach, Jennifer A. ^{[33
]}

Ye, J. Christine ^{[34
]}

Dwyer, Mary A. ^{[35
]}

Sundar, Hema ^{[35
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[3] Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA

[4] UT Southwestern Simmons Comprehens Canc Ctr, Dallas, TX USA

[5] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA

[6] Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[7] Duke Canc Inst, Durham, NC USA

[8] Mayo Clin, Canc Ctr, Rochester, MN USA

[9] Stanford Canc Inst, Stanford, CA USA

[10] ONeal Comprehens Canc Ctr UAB, Birmingham, AL USA

[11] UCLA, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

[12] Univ Wisconsin, Carbone Canc Ctr, Madison, WI 53706 USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO 63110 USA

[15] Washington Univ, Sch Med, St Louis, MO USA

[16] Univ Tennessee, Hlth Sci Ctr, St Jude Chidrens Res Hosp, Knoxville, TN 37996 USA

[17] Roswel Pk Comprehens Canc Ctr, Buffalo, NY USA

[18] Univ Hosp Seidman Canc Ctr, Case Comprehensve Canc Ctr, Cleveland, OH USA

[19] Cleveland Clin, Tausslg Canc Inst, Cleveland, OH 44106 USA

[20] UC Davis Comprehens Canc Ctr, Davis, CA USA

[21] Univ Colorado, Canc Ctr, Boulder, CO 80309 USA

[22] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[23] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[24] UC San Diego Moores Canc Ctr, San Diego, CA USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[26] Mem Sloan Kettering Canc Ctr, Ithaca, NY USA

[27] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[28] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[29] City Hope Natl Med Ctr, Duarte, CA USA

[30] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[31] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA

[32] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[33] Ohio State Univ, Comprehenslve Canc Ctr, James Canc Hosp & Solove Res Inst, Columbus, OH 43210 USA

[34] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[35] Natl Comprehens Canc Network, Philadelphia, PA USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2022年 / 20卷 / 06期

关键词：

MINIMAL RESIDUAL DISEASE; CHLORAMBUCIL PLUS OBINUTUZUMAB; FLOW-CYTOMETRY; OPEN-LABEL; 1ST-LINE TREATMENT; FOLLOW-UP; PHASE-II; IBRUTINIB; VENETOCLAX; CLL;

D O I：

10.6004/jnccn.2022.0031

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton???s tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as an effective chemotherapy-free option for patients with previously untreated or relapsed/refractory CLL/SLL. Undetectable minimal residual disease after the end of treatment is emerging as an important predictor of progression-free and overall survival for patients treated with fixed-duration BCL-2 inhibitor-based treatment. These NCCN Guidelines Insights discuss the updates to the NCCN Guidelines for CLL/ SLL specific to the use of chemotherapy-free treatment options for patients with treatment-na??ve and relapsed/refractory disease.

引用

页码：622 / 634

页数：13

共 50 条

[31] Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines
Coit, Daniel G.
Andtbacka, Robert
Anker, Christopher J.
Bichakjian, Christopher K.
Carson, William E., III
Daud, Adil
DiMaio, Dominick
Fleming, Martin D.
Guilds, Valerie
Halpern, Allan C.
Hodi, F. Stephen, Jr.
Kelley, Mark C.
Khushalani, Nikhil I.
Kudchadkar, Ragini R.
Lange, Julie R.
Lind, Anne
Martini, Mary C.
Olszanski, Anthony J.
Pruitt, Scott K.
Ross, Merrick I.
Swetter, Susan M.
Tanabe, Kenneth K.
Thompson, John A.
Trisal, Vijay
Urist, Marshall M.
McMillian, Nicole
Ho, Maria
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (04): : 395 - 407
[32] Survivorship, Version 1.2022 Featured Updates to the NCCN Guidelines
Sanft, Tara
Day, Andrew
Peterson, Lindsay
Rodriguez, M. Alma
Ansbaugh, Shannon
Armenian, Saro
Baker, K. Scott
Ballinger, Tarah
Broderick, Gregory
Demark-Wahnefried, Wendy
Dickinson, Kristin
Fairman, Nathan Paul
Friedman, Debra L.
Goldman, Mindy
Henry, Norah Lynn
Hill-Kayser, Christine
Hudson, Melissa
Khakpour, Nazanin
Koura, Divya
McDonough, Allison L.
Melisko, Michelle
Mooney, Kathi
Moore, Halle C. F.
Moryl, Natalie
Neuman, Heather
O'Connor, Tracey
Overholser, Linda
Paskett, Electra D.
Patel, Chirayu
Pirl, William
Porpiglia, Andrea
Ruddy, Kathryn J.
Schapira, Lidia
Shockney, Lillie
Smith, Sophia
Syrjala, Karen L.
Tevaarwerk, Amye
Yang, Eric H.
Zee, Phyllis
McMillian, Nicole R.
Freedman-Cass, Deborah A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (10): : 1080 - 1090
[33] Insights From the informCLL Registry: Real-World Application of NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Ghosh, Nilanjan
Brander, Danielle
Mato, Anthony R.
Sharman, Jeff P.
Gutierrez, Meghan
Naganuma, Maoko
Upasani, Sandhya
Alagappan, Divi
Huang, Qing
Young, Alex
Barrientos, Jacqueline C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S317 - S317
[34] NCCN Guidelines® Insights Myeloproliferative Neoplasms, Version 2.2018 Featured Updates to the NCCN Guidelines
Mesa, Ruben A.
Jamieson, Catriona
Bhatia, Ravi
Deininger, Michael W.
Fletcher, Christopher D.
Gerds, Aaron T.
Gojo, Ivana
Gotlib, Jason
Gundabolu, Krishna
Hobbs, Gabriela
McMahon, Brandon
Mohan, Sanjay R.
Oh, Stephen
Padron, Eric
Papadantonakis, Nikolaos
Pancari, Philip
Podoltsev, Nikolai
Rampal, Raajit
Ranheim, Erik
Reddy, Vishnu
Rein, Lindsay A. M.
Scott, Bart
Snyder, David S.
Stein, Brady L.
Talpaz, Moshe
Verstovsek, Srdan
Wadleigh, Martha
Wang, Eunice S.
Bergman, Mary Anne
Gregory, Kristina M.
Sundar, Hema
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (10): : 1193 - 1207
[35] NCCN Guidelines® Insights Palliative Care, Version 2.2017 Featured Updates to the NCCN Guidelines
Dans, Maria
Smith, Thomas
Back, Anthony
Baker, Justin N.
Bauman, Jessica R.
Beck, Anna C.
Block, Susan
Campbell, Toby
Case, Amy A.
Dalal, Shalini
Edwards, Howard
Fitch, Thomas R.
Kapo, Jennifer
Kutner, Jean S.
Kvale, Elizabeth
Miller, Charles
Misra, Sumathi
Mitchell, William
Portman, Diane G.
Spiegel, David
Sutton, Linda
Szmuilowicz, Eytan
Temel, Jennifer
Tickoo, Roma
Urba, Susan G.
Weinstein, Elizabeth
Zachariah, Finly
Bergman, Mary Anne
Scavone, Jillian L.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (08): : 989 - 997
[36] NCCN Guidelines® Insights Bladder Cancer, Version 5.2018 Featured Updates to the NCCN Guidelines
Flaig, Thomas W.
Spiess, Philippe E.
Agarwal, Neeraj
Bangs, Rick
Boorjian, Stephen A.
Buyyounouski, Mark K.
Downs, Tracy M.
Efstathiou, Jason A.
Friedlander, Terence
Greenberg, Richard E.
Guru, Khurshid A.
Noah Hahn
Herr, Harry W.
Hoimes, Christopher
Inman, Brant A.
Jimbo, Masahito
Kader, A. Karim
Lele, Subodh M.
Meeks, Joshua J.
Michalski, Jeff
Montgomery, Jeffrey S.
Pagliaro, Lance C.
Pal, Sumanta K.
Patterson, Anthony
Petrylak, Daniel P.
Plimack, Elizabeth R.
Pohar, Kamal S.
Porter, Michael P.
Preston, Mark A.
Sexton, Wade J.
Siefker-Radtke, Arlene O.
Tward, Jonathan
Wile, Geoffrey
Johnson-Chilla, Alyse
Dwyer, Mary A.
Gurski, Lisa A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (09): : 1041 - 1053
[37] NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Benson, Al B., III
Venook, Alan P.
Al-Hawary, Mahmoud M.
Cederquist, Lynette
Chen, Yi-Jen
Ciombor, Kristen K.
Cohen, Stacey
Cooper, Harry S.
Deming, Dustin
Engstrom, Paul F.
Garrido-Laguna, Ignacio
Grem, Jean L.
Grothey, Axel
Hochster, Howard S.
Hoffe, Sarah
Hunt, Steven
Kamel, Ahmed
Kirilcuk, Natalie
Krishnamurthi, Smitha
Messersmith, Wells A.
Meyerhardt, Jeffrey
Miller, Eric D.
Mulcahy, Mary F.
Murphy, James D.
Nurkin, Steven
Saltz, Leonard
Sharma, Sunil
Shibata, David
Skibber, John M.
Sofocleous, Constantinos T.
Stoffel, Elena M.
Stotsky-Himelfarb, Eden
Willett, Christopher G.
Wuthrick, Evan
Gregory, Kristina M.
Freedman-Cass, Deborah A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (04): : 359 - 369
[38] NCCN Guidelines® Insights Breast Cancer, Version 1.2017 Featured Updates to the NCCN Guidelines
Gradishar, William J.
Anderson, Benjamin O.
Balassanian, Ron
Blair, Sarah L.
Burstein, Harold J.
Cyr, Amy
Elias, Anthony D.
Farrar, William B.
Forero, Andres
Giordano, Sharon Hermes
Goetz, Matthew P.
Goldstein, Lori J.
Isakoff, Steven J.
Lyons, Janice
Marcom, P. Kelly
Mayer, Ingrid A.
McCormick, Beryl
Moran, Meena S.
O'Regan, Ruth M.
Patel, Sameer A.
Pierce, Lori J.
Reed, Elizabeth C.
Salerno, Kilian E.
Schwartzberg, Lee S.
Sitapati, Amy
Smith, Karen Lisa
Smith, Mary Lou
Soliman, Hatem
Somlo, George
Telli, Melinda
Ward, John H.
Shead, Dorothy A.
Kumar, Rashmi
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (04): : 433 - +
[39] NCCN Guidelines® Insights Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines
Clark, Peter E.
Spiess, Philippe E.
Agarwal, Neeraj
Bangs, Rick
Boorjian, Stephen A.
Buyyounouski, Mark K.
Efstathiou, Jason A.
Flaig, Thomas W.
Friedlander, Terence
Greenberg, Richard E.
Guru, Khurshid A.
Hahn, Noah
Herr, Harry W.
Holmes, Christopher
Inman, Brant A.
Kader, A. Karim
Kibel, Adam S.
Kuzel, Timothy M.
Lele, Subodh M.
Meeks, Joshua J.
Michalski, Jeff
Montgomery, Jeffrey S.
Pagliaro, Lance C.
Pal, Sumanta K.
Patterson, Anthony
Petrylak, Daniel
Plimack, Elizabeth R.
Pohar, Kamal S.
Porter, Michael P.
Sexton, Wade J.
Siefker-Radtke, Arlene O.
Sonpavde, Guru
Tward, Jonathan
Wile, Geoffrey
Dwyer, Mary A.
Smith, Courtney
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10): : 1213 - 1224
[40] NCCN Guidelines® Insights Thyroid Carcinoma, Version 2.2018 Featured Updates to the NCCN Guidelines
Haddad, Robert I.
Nasr, Christian
Bischoff, Lindsay
Busaidy, Naifa Lamki
Byrd, David
Callender, Glenda
Dickson, Paxton
Duh, Quan-Yang
Ehya, Hormoz
Goldner, Whitney
Haymart, Megan
Hoh, Carl
Hunt, Jason P.
Iagaru, Andrei
Kandeel, Fouad
Kopp, Peter
Lamonica, Dominick M.
McIver, Bryan
Raeburn, Christopher D.
Ridge, John A.
Ringel, Matthew D.
Scheri, Randall P.
Shah, Jatin P.
Sippel, Rebecca
Smallridge, Robert C.
Sturgeon, Cord
Wang, Thomas N.
Wirth, Lori J.
Wong, Richard J.
Johnson-Chilla, Alyse
Hoffmann, Karin G.
Gurski, Lisa A.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2018, 16 (12): : 1429 - 1440

← 1 2 3 4 5 →